Aronia melanocarpa L. breast carcinoma epigenetics in vitro models mechanism of action rodent models

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2024
Historique:
received: 12 07 2024
accepted: 17 09 2024
medline: 22 10 2024
pubmed: 22 10 2024
entrez: 22 10 2024
Statut: epublish

Résumé

Within oncology research, there is a high effort for new approaches to prevent and treat cancer as a life-threatening disease. Specific plant species that adapt to harsh conditions may possess unique properties that may be utilized in the management of cancer. Chokeberry fruit is rich in secondary metabolites with anti-cancer activities potentially useful in cancer prevention and treatment. Based on mentioned hypothesis, the main goal of our study was to evaluate the antitumor effects of dietary administered The dominant metabolites in the This study is the first to analyze the antitumor effect of

Identifiants

pubmed: 39435289
doi: 10.3389/fonc.2024.1463656
pmc: PMC11491292
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1463656

Informations de copyright

Copyright © 2024 Dvorska, Mazurakova, Lackova, Sebova, Kajo, Samec, Brany, Svajdlenka, Treml, Mersakova, Strnadel, Adamkov, Lasabova, Biringer, Mojzis, Büsselberg, Smejkal, Kello and Kubatka.

Déclaration de conflit d'intérêts

The authors declare the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Dana Dvorska (D)

Biomedical Centre Martin, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia.

Alena Mazurakova (A)

Department of Anatomy, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia.

Lenka Lackova (L)

Department of Histology and Embryology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia.

Dominika Sebova (D)

Department of Pharmacology, Faculty of Medicine, P. J. Šafárik University, Košice, Slovakia.

Karol Kajo (K)

Department of Pathology, St. Elisabeth Oncology Institute, Bratislava, Slovakia.

Marek Samec (M)

Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia.

Dusan Brany (D)

Biomedical Centre Martin, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia.

Emil Svajdlenka (E)

Department of Natural Drugs, Faculty of Pharmacy, Masaryk University, Brno, Czechia.

Jakub Treml (J)

Department of Molecular Pharmacy, Faculty of Pharmacy, Masaryk University, Brno, Czechia.

Sandra Mersakova (S)

Biomedical Centre Martin, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia.

Jan Strnadel (J)

Biomedical Centre Martin, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia.

Marian Adamkov (M)

Department of Histology and Embryology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia.

Zora Lasabova (Z)

Department of Molecular Biology and Genomics, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia.

Kamil Biringer (K)

Clinic of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia.

Jan Mojzis (J)

Department of Pharmacology, Faculty of Medicine, P. J. Šafárik University, Košice, Slovakia.

Dietrich Büsselberg (D)

Department of Physiology and Biophysics, Weill Cornell Medicine in Qatar, Qatar Foundation, Doha, Qatar.

Karel Smejkal (K)

Department of Natural Drugs, Faculty of Pharmacy, Masaryk University, Brno, Czechia.

Martin Kello (M)

Department of Pharmacology, Faculty of Medicine, P. J. Šafárik University, Košice, Slovakia.

Peter Kubatka (P)

Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia.

Classifications MeSH